文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

低剂量半身放疗作为复发性前列腺癌的治疗选择:一项2期单臂试验

Low-Dose Hemibody Radiation, a Treatment Option for Recurrent Prostate Cancer: A Phase 2 Single-Arm Trial.
PubMed 文献 · Adv Radiat Oncol · 2022-09-10

这项2期两阶段单臂试验纳入16例复发性前列腺癌患者,接受每周2次、每次150 mGy非靶向放疗,连续5周,15例完成研究。主要终点为PSA降低至少50%,但3个月时PSA最大降幅为40.5%,研究未达到主要目标;低剂量放疗耐受性良好,最常见不良事件为治疗期间轻度乏力(n=4)。

要点

  • 3个月时PSA最大降幅为40.5%,未达到主要终点(PSA降低至少50%)。
  • 8例参与者未接受额外干预,其中3例在治疗后至少1年内PSA仅有轻微波动。
  • 最常见不良事件为治疗期间轻度乏力(n=4),随访期未持续;无因安全性或血液学异常退出。

核心结论

  • 研究未达到主要目标,但低剂量放疗可能通过延缓PSA升高成为部分复发性前列腺癌患者的潜在治疗选择。
  • 低剂量放疗耐受性良好,毒性轻微,生活质量无变化。

研究设计与样本

  • 2期两阶段单臂试验,纳入16例复发性前列腺癌患者,15例完成研究。
  • 干预为每周2次、每次150 mGy非靶向放疗,连续5周。
  • 主要终点为PSA水平降低至少50%。

主要发现

  • 3个月时观察到PSA最大降幅为40.5%。
  • 8例参与者未接受任何额外干预,其中3例在治疗后至少1年内PSA仅有轻微波动。
  • 最常见不良事件为治疗期间轻度乏力(n=4),随访期未持续。
  • 无参与者因安全性担忧或血液学异常(即血小板≤50×10^9/L、白细胞≤3×10^9/L、粒细胞≤2×10^9/L)退出。

临床怎么用

  • 作者认为低剂量放疗可能通过延缓PSA升高成为部分复发性前列腺癌患者的潜在治疗选择。
  • 作者报告低剂量放疗耐受性良好,毒性轻微,生活质量无变化。

局限性

  • 研究未达到主要目标(PSA降低至少50%)。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Nontargeted low-dose ionizing radiation has been proposed as a cancer therapeutic for several decades; however, questions remain about the duration of hematological changes and optimal dosing regimen. Early studies delivering fractionated low doses of radiation to patients with cancer used varying doses and schedules, which make it difficult to standardize a successful dose and scheduling system for widespread use. The aim of this phase 2 two-stage trial was to determine whether low-dose radiation therapy (LD-RT) reduced prostate-specific antigen (PSA) in patients with recurrent prostate cancer in efforts to delay initiation of conventional therapies that are known to decrease quality of life. The primary study outcome was reduction in PSA levels by at least 50%. METHODS AND MATERIALS: Sixteen patients with recurrent prostate cancer were recruited and received 2 doses of 150 mGy of nontargeted radiation per week, for 5 consecutive weeks, with 15 participants completing the study. RESULTS: A maximal response of 40.5% decrease in PSA at 3 months was observed. A total of 8 participants remained off any additional interventions, of whom 3 had minor fluctuations in PSA for at least 1 year after treatment. The most common adverse event reported was mild fatigue during active treatment (n = 4), which did not persist in the follow-up period. No participants withdrew due to safety concerns or hematological abnormalities (ie, platelet ≤50 × 109/L, leukocyte ≤3 × 109/L, granulocyte ≤2 × 109/L). CONCLUSIONS: Our study did not meet the primary objective; however, LD-RT may be a potential therapy for some patients with recurrent prostate cancer by stalling rising PSA. This study also demonstrates that low-dose radiation is well tolerated by participants with minimal toxicities and no change in quality of life.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Dayes IS, Kennedy AE, Parpia S, et al. Low-Dose Hemibody Radiation, a Treatment Option for Recurrent Prostate Cancer: A Phase 2 Single-Arm Trial. Adv Radiat Oncol. 2022. PMID: 36483063. doi:10.1016/j.adro.2022.101066

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。